A newly published study in the BMJ finds that almost 60% of drugs receiving new indications from the US Food and Drug Administration (FDA) do not add high therapeutic value to patients. As a result, the researchers argue that patients and providers should be aware and that prices should be set accordingly.
According to Zachary Brennan, “The researchers also noted that as the additional approvals piled up, those follow-on indications were less likely to have a high-value rating, as second approvals for an indication were 36% to 37% less likely to have a high-value rating compared with the first approval, and third competitor approvals were 45% to 52% less likely to have a high rating.”
To read more, click here.
(Source: Endpoints News, July 6th, 2023)